Americans seek ibogaine treatment abroad while FDA trial proceeds stateside
Americans travel to Mexico for ibogaine treatment as regulatory barriers persist domestically despite clinical promise.
Event / Politics
Ibogaine FDA Approval Clinical Trial
FDA approval of the first clinical trial for ibogaine, a psychedelic drug, examining its potential for treating PTSD, addiction, and other mental health conditions, alongside safety and regulatory considerations.
6 reported locations
Daily activity
0 articles0 articles
2026-08-18 to 2026-11-15 · UTC publication dates
Coverage begins 19 Apr, 00:07 UTC
Follow the documented timeline or explore the related reporting.
What happened
President Trump promotes increased access to psychedelics at White House event
President Donald Trump promoted increased access to psychedelic drugs at a White House event in April 2026, specifically highlighting ibogaine's potential therapeutic applications. Veterans recounted anecdotal experiences with the drug during the event.
FDA approves first clinical trial of psychedelic drug ibogaine
The Food and Drug Administration approved the first clinical trial of ibogaine, a psychedelic drug derived from the root of a West African shrub. The drug has been used traditionally for ceremonial and spiritual purposes and is now undergoing regulatory evaluation for potential therapeutic applications.
Stanford University study finds ibogaine reduces PTSD and depression symptoms in combat veterans
Stanford University scientists conducted a study finding that ibogaine nearly eliminated symptoms of post-traumatic stress disorder, depression, and anxiety in combat veterans with traumatic brain injuries. The study enrolled 30 veterans and was observational in design, meaning all participants knew they were receiving the drug.
Research indicates ibogaine reduces substance use cravings including opioid addiction
Research studies suggest ibogaine can powerfully reduce cravings in people with substance use disorders, including opioid addiction. These studies indicate potential therapeutic applications for treating addiction-related conditions.
UC Davis scientists develop synthetic production method for ibogaine
Chemist and neuroscientist David Olson at the University of California, Davis published a synthetic route for producing ibogaine from its plant-derived source. This development provides a foundation for further study and potential improvement of the drug.
Ibogaine causes dangerous cardiac side effects including irregular heartbeat
In addition to its activity in the brain, ibogaine binds to proteins in the heart, leading some people to experience a dangerously irregular heartbeat. Clinical research reviews consistently warn against severe medical complications including heart attacks and death associated with ibogaine use.
Americans travel abroad for ibogaine treatment at wellness clinics
In recent years, Americans have been traveling abroad, typically to Mexico, and spending thousands of dollars to receive ibogaine at wellness clinics. These clinics claim to treat various conditions including post-traumatic stress disorder, addiction, depression, and traumatic brain injuries.
FDA Commissioner states ibogaine would require controlled clinical setting if approved
FDA Commissioner Marty Makary told CBS News that if ibogaine eventually receives approval, it would have to be provided in "a very controlled and supervised medical, clinical setting" to ensure safe administration.
Ibogaine carries serious risk of fatal heart rhythm disturbances
Studies demonstrate that ibogaine can cause dangerous heart rhythm disturbances, which can be fatal. A 2023 review of 24 studies including 705 people indicated the risk of death from heart problems is concerning, with at least 27 documented deaths after taking ibogaine.
Texas Governor Greg Abbott signed bill funding $50 million ibogaine research
Texas Governor Greg Abbott signed a bill approving $50 million for ibogaine research efforts in the state.
Three psychedelics added to FDA National Priority Voucher pilot program
FDA Commissioner Marty Makary announced that three psychedelics would be added to the National Priority Voucher pilot program, a pathway designed to dramatically reduce review times for drug and biological products that align with U.S. national health priorities. The FDA designated these psychedelics as addressing an unmet public health need with potentially promising treatments.
Ibogaine shows promise in treating PTSD, depression, and addiction in preliminary research
Preliminary research indicates ibogaine has potential to treat post-traumatic stress disorder, depression, anxiety, addiction, and traumatic brain injury. Clinical trials have shown success in treating depression, anxiety, PTSD, suicidal ideation, and substance abuse. However, scientific evidence consists mostly of small observational studies and open-label trials, with only one double-blind, placebo-controlled randomized clinical trial completed so far.
Ibogaine classified as Schedule I controlled substance in United States
Ibogaine is currently classified as a Schedule I controlled substance by the Drug Enforcement Administration, grouped alongside heroin and ecstasy. This classification has historically prevented extensive research. Americans seeking treatment have traveled to unregulated clinics, often in Mexico or the Caribbean.
Over 14 million American adults diagnosed with serious mental illness
More than 14 million American adults have been diagnosed with serious mental illness, according to White House data cited during the ibogaine policy announcement.
President Trump signs executive order to expedite psychedelic ibogaine research
President Trump signed an executive order on Saturday to accelerate research and access to ibogaine, a psychedelic drug currently classified as Schedule I. The order removes legal restrictions preventing extensive studies into the drug and establishes FDA protocols for safe therapeutic use of psychedelics. The federal government committed a $50 million research investment into ibogaine.
FDA creates pathway for ibogaine under Right To Try rule for critically ill patients
The FDA is opening a pathway for ibogaine to be administered to critically ill patients under the Food and Drug Administration's Right To Try rule, which allows desperately ill patients access to experimental treatments outside standard trials. The FDA will also begin the process to allow researchers to conduct human trials into ibogaine's use.
Over 6,000 U.S. veterans commit suicide annually
More than 6,000 U.S. veterans commit suicide every year, according to White House data. This has been cited as a major public health concern driving efforts to develop new treatment options for PTSD and mental health conditions affecting the veteran population.
Read the coverage
2 alternative perspectives
FDA Mandates Controlled Clinical Settings for Potential Ibogaine Approval
FDA mandates controlled clinical settings for ibogaine if approved, balancing access with safety oversight.
FDA-Approved Trial Confirms Ibogaine's Clinical Efficacy and Production Viability
FDA-approved ibogaine trial confirms clinical efficacy; synthetic production method enables pharmaceutical scaling.
Mental health crisis drives urgent push for unconventional treatments
America's mental health crisis fuels push to reconsider treatments for millions suffering serious illness and high-risk populations.
Ibogaine's Clinical Promise Clashes With Serious Cardiac Safety Risks
Ibogaine demonstrates therapeutic promise against serious conditions but poses fatal cardiac risks requiring careful clinical management.
Trump Executive Order Fast-Tracks Ibogaine Through FDA Regulatory Framework
Executive order establishes FDA pathways for ibogaine while Texas funds $50 million research initiative.